Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 1801–1850 of 18397
the Board has appointed Jessica Buss as the Chief Executive Officer of the Company, effective immediately.
the Company and Tarak B. Mehta, the President and Chief Executive Officer of the Company, had mutually agreed that Mr. Mehta would depart from the Company, including resigning as a member of the Company’s Board of Directors (the “Board”), effective immediately.
the Board had appointed Richard G. Kyle as the interim President and Chief Executive Officer of the Company, effective immediately.
On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company ”), would end effective March 31, 2025.
the Board appointed Steve Forte to serve as the Company’s President and Chief Executive Officer in addition to his current role as the Company’s Chief Financial Officer, effective as of the Effective Date.
On March 31, 2025, Lloyd Segal, President and Chief Executive Officer of Repare Therapeutics Inc. (the “ Company ”), notified the board of directors (the “ Board ”) of the Company of his resignation from his positions as President and Chief Executive Officer and as a member of the Board, effective April 11, 2025
On March 27, 2025, the Board terminated Michael T. Broderick from his positions as President and Chief Executive Officer of the Company effective immediately.
On March 28, 2025, the Board of Directors (“Board”) of Monro, Inc. (the “Company”) appointed Peter Fitzsimmons to serve as the President and Chief Executive Officer of the Company effective immediately.
On March 27, 2025, the Board of Directors appointed Jaime Fickett, the Company’s current Interim Chief Financial Officer, to the position of Chief Financial Officer, effective immediately.
Donald A. Moul has been appointed as TVA’s new President and Chief Executive Officer, starting April 9, 2025.
He will succeed Jeffrey J. Lyash, who is retiring from his position with TVA and will continue to serve for up to 30 days to support the transition.
On and effective as of March 28, 2025, the Board of Directors of the Company approved the appointment of Mr. Jackola as the Company’s Executive Vice President and Chief Financial Officer.
the Company's Chief Financial Officer, Sunit Patel, resigned, and Valarie Sheppard, a member of the Company's Board of Directors (the 'Board'), assumed the role of Interim Chief Financial Officer, effective March 14, 2025.
the Company's Chief Financial Officer, Sunit Patel, resigned, and Valarie Sheppard, a member of the Company's Board of Directors (the 'Board'), assumed the role of Interim Chief Financial Officer, effective March 14, 2025.
On February 25, 2025, Mr. Ernest Scheidemann informed First Choice Healthcare Solutions, Inc. (the “Company”) of his resignation as the Interim Chief Financial Officer of the Company, effective as of February 25, 2025.
Joseph Hummel resigned as Chief Executive Officer of Twin Hospitality Group Inc.
appointed Kenneth Kuick, the Company’s current Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective upon Mr. Hummel’s departure.
Effective as of March 28, 2025, the Board of Directors appointed Nicolas Link (44) as the new Chief Executive Officer of the Company.
Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer
The Board appointed Constantine Nkafu to serve as the Company’s interim CEO.
the Board appointed the Company’s Managing Director and Head of Infrastructure, Mr. Daniel De Boer, age 39, as the Company’s Interim CEO, effective April 1, 2025.
On March 28, 2025, the Board appointed Rami Hasani as the Company’s Executive Vice President, Chief Financial Officer, effective as of April 1, 2025.
Ms. Olshan will step down as the Company’s Chief Executive Officer and President ("CEO") and as a member of the Board effective as of April 11, 2025
The Board has appointed Board Chairman Adam Metz as Interim Chief Executive Officer and President ("Interim CEO") as of the Separation Date.
On March 28, 2025, Werner Cautreels notified Traws Pharma, Inc. (the Company”) of his decision to retire and resign from his role as Chief Executive Officer of the Company, effective as of the close of business on the day that the Company files its Annual Report on Form 10-K for its 2024 fiscal year
Effective as of the Termination Date, the Board appointed Iain Dukes to serve as the Company’s Interim Chief Executive Officer.
On March 27, 2025, the Board appointed Thomas Hansen as interim Chief Financial Officer
On March 24, 2025, Gerard Waldt notified the Board of Trustees (the “Board”) of T. Rowe Price OHA Select Private Credit Fund (the “Company”) of his resignation as the Company’s Chief Financial Officer
On March 24, 2025, Gerard Waldt notified the Board of Managers (the “Board”) of OHA Senior Private Lending Fund (U), LLC (the “Company”) of his resignation as the Company’s Chief Financial Officer in order to pursue other professional opportunities.
On March 27, 2025, the Board appointed Thomas Hansen as interim Chief Financial Officer of the Company effective as of the close of business on April 28, 2025.
In connection with the consummation of the Merger, James R. Scapa, Matthew Brown and Stephanie Buckner ceased to serve as the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, respectively, of the Surviving Corporation.
In connection with the consummation of the Merger, James R. Scapa, Matthew Brown and Stephanie Buckner ceased to serve as the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, respectively, of the Surviving Corporation.
Immediately after the consummation of the Merger, Anthony L. Hemmelgarn and Timo Nentwich have been appointed as the Chief Executive Officer and Chief Financial Officer, respectively, of the Surviving Corporation.
Immediately after the consummation of the Merger, Anthony L. Hemmelgarn and Timo Nentwich have been appointed as the Chief Executive Officer and Chief Financial Officer, respectively, of the Surviving Corporation.
John Power, the former President and CEO of the Company resigned as President and CEO
Koby Kushner was appointed to serve as President and CEO of the Company
On March 21, 2025, Jessica Buss notified Argo Group International Holdings, Inc. (the “Company”) of her resignation as Chief Executive Officer of the Company, effective immediately
Christopher Donahue, the Company’s Chief Financial Officer, was appointed as the Chief Executive Officer of the Company
David Chan, the Company’s Chief Accounting Officer, was appointed as the Chief Financial Officer of the Company
On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.
Maria Maccecchini will continue to serve as principal financial officer on an interim basis.
On March 27, 2025, the Board of Directors (the “Board”) of Wolfspeed, Inc. (the “Company”) appointed Robert Feurle to serve as the Company’s Chief Executive Officer and a member of the Board, effective May 1, 2025
Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.
Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).
The employment of Thomas Butler as Chief Executive Officer of the Company ended on March 25, 2025 (the “Effective Date”).
Dr. Hitchcock, a member of the Board, was appointed as the Company’s interim Chief Executive Officer and principal executive officer
Rainer (Ramses) Erdtmann, the Company’s President, Chief Operating Officer and a member of the Board, was appointed as the Company’s principal financial officer and principal accounting officer
On March 24, 2025, Pacific Biosciences of California, Inc. (the “Company”) entered into an offer letter with Jim R. Gibson to serve as its Chief Financial Officer. Mr. Gibson will be appointed as the Company’s Chief Financial Officer and principal financial officer effective as of as his first date of employment, which is anticipated to be March 31, 2025
Christian Henry, the Company’s President and Chief Executive Officer, who has been serving also as the Company’s interim Chief Financial Officer and principal financial officer since December 6, 2024 will cease serving as interim Chief Financial Officer and principal financial officer upon commencement of Mr. Gibson’s employment but will continue serving as the Company’s President and Chief Executive officer.
John Witek, who served as Interim Chief Financial Officer and Chief Accounting Officer, is retiring effective March 31, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.